Johnson & Johnson (JNJ) 2024 10-K Earnings Analysis
Johnson & Johnson2024 Earnings Analysis
74/100
Johnson & Johnson's FY2024 10-K reflects the first full year after the Kenvue consumer-health spin-off — a leaner company focused on Innovative Medicine and MedTech. Revenue of $88.8B and net income of $14.1B translate to 19.7% ROE and $19.9B FCF. The dominant strategic event is pending: STELARA, JNJ's $10B+ immunology blockbuster, entered biosimilar competition in 2025, and the 10-K's Risk Factors open by acknowledging that 'for the Company's Innovative Medicine businesses, loss of patent exclusivity for a product often is followed by a substantial reduction in sales.'
Filing analysis
Johnson & Johnson 2024 10-K Analysis
This page reads Johnson & Johnson's 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 74/100, or grade C.
JNJ Earnings Quality
The earnings-quality module scores 79/100, with Gross Margin: 69.1%, CF/Net Income: 1.72x. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
JNJ Economic Moat Analysis
The moat-strength module scores 78/100, with Patent-Protected Portfolio: Strong (eroding), Innovative Medicine Franchise: Strong. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
JNJ Free Cash Flow vs Net Income
CF/Net Income: 1.72x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 76/100. For the diagnostic, start with cash flow vs net income.
JNJ Key Risks from the Annual Report
The risk module scores 64/100, with STELARA Patent Cliff: High, Talc Litigation Residual: Managed. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is JNJ a High Quality Earnings Stock?
Based on this 2024 filing, JNJ needs a closer read before it qualifies as a high-quality earnings candidate: the overall grade is C, and the earnings-quality score is 79/100. This is a research screen, not investment advice.
Read the report first
Understand Johnson & Johnson first, then decide if it belongs on your watchlist
The JNJ score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep JNJ with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the JNJ report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Gross margin of 69.1% — pharma-like despite the MedTech drag (which runs lower margins). The 10-K highlights the Innovative Medicine segment's key products: STELARA, REMICADE, DARZALEX, TREMFYA, ERLEADA, CARVYKTI — all high-margin patent-protected specialty therapeutics.
Operating cash flow of $24.3B on $14.1B net income yields 1.72x — elevated by non-cash charges (patent amortization, restructuring) that depress reported NI without affecting cash. Cash-based earnings are stronger than GAAP suggests.
Revenue of $88.8B grew modestly as the post-Kenvue baseline solidifies. Innovative Medicine and MedTech each contributed, but the growth is muted ahead of STELARA biosimilar erosion. The 10-K explicitly flags patent-cliff dynamics.
J&J spends approximately 19% of revenue on R&D — high even by pharma standards, reflecting the intensive reinvestment required to replace STELARA and build the next immunology/oncology franchise. The 10-K documents an extensive pipeline across immunology, oncology (CARVYKTI, DARZALEX, TECVAYLI), and pulmonary hypertension (OPSUMIT, UPTRAVI).
Earnings quality scores 79/100. The 69.1% gross margin and 1.72x cash conversion signal high-quality underlying economics, but the top-line deceleration to +4.7% previews the STELARA patent-cliff headwind. The 10-K is explicit about this: 'loss of patent exclusivity for a product often is followed by a substantial reduction in sales as competitors gain regulatory approval for generic, biosimilar and other competing products.' FY2024 shows J&J earning at near-peak on STELARA before the biosimilar rebalance; the quality metrics may read differently in FY2025-26 as biosimilar competitors ramp per the 10-K Risk Factors.
Moat Strength
The 10-K lists 15+ key products protected by patents, each backed by 'a significant number of patents in the U.S. and other countries relating to their products, product uses, formulations and manufacturing processes.' But the filing also acknowledges the FY2024 10-K Risk Factors cite patent challenges seeking to launch generic and biosimilar alternatives as a recurring exposure — the moat is strong per molecule but expires on fixed timelines.
Therapeutic franchises across Immunology (STELARA, TREMFYA, REMICADE), Oncology (DARZALEX, CARVYKTI, ERLEADA), and Cardiovascular (XARELTO, OPSUMIT) generate recurring prescription-driven revenue from installed physician/patient relationships. Multi-year specialty therapy lock-in is real — oncologists don't casually switch CAR-T protocols.
J&J's MedTech portfolio (cardiovascular, orthopaedics, surgery, vision — including ACUVUE contact lenses and TECNIS intraocular lenses) embeds surgeons into procedure-specific technology. The 10-K highlights orthopaedic implants, electrophysiology (Abiomed), and Shockwave — hardware + training creates multi-year switching costs.
The 10-K discloses J&J operates '64 manufacturing facilities' and sources from 'thousands of suppliers around the world.' This manufacturing footprint supports both Innovative Medicine and MedTech. Per the FY2024 10-K manufacturing and quality disclosures, scale-based reliability in FDA-regulated production is a durable competitive factor.
Moat strength scores 78/100 — strong but facing the largest patent cliff in J&J's modern history. The Innovative Medicine franchise is formidable on FY2024 numbers, but the 10-K's explicit Risk Factor about 'loss of patent exclusivity' applies directly to STELARA, which is already under biosimilar pressure. MedTech provides diversification — surgeon training and procedure-specific workflows create real switching costs. The 64-facility manufacturing footprint adds scale reliability that smaller competitors can't match. The moat's width depends on whether the post-Kenvue pipeline (CARVYKTI, TREMFYA expansion, next-gen oncology) fills the STELARA void by FY2027.
Capital Allocation
FCF of $19.9B on $88.8B revenue = 22.4% FCF margin. OCF-to-FCF gap is just $4.4B (CapEx), reflecting the pharma/medtech capital profile — most spending is R&D-expensed, not capitalized.
ROE of 19.7% (NI $14.1B / Equity $71.5B) — solid quality return, not engineered with excessive leverage. Debt ratio of 60.3% is moderate given the steady cash flows and predictable pharma/medtech economics.
Goodwill of $44.2B = 24.5% of $180.1B assets — elevated, reflecting J&J's acquisition-heavy pipeline building (Abiomed, Shockwave, various specialty pharma). Not alarming for a pharma, but worth monitoring as the STELARA cliff tests the earning power of acquired franchises.
J&J is a dividend aristocrat with 62+ consecutive years of raises — a commitment that signals management's capital-allocation discipline. The dividend is covered multiple times by FCF of $19.9B, leaving room for buybacks and strategic tuck-in M&A.
Capital allocation scores 76/100. The post-Kenvue J&J is structured for capital return: 19.7% ROE without Apple-style leverage, $19.9B FCF funding a multi-decade dividend-growth record, and moderate 60.3% debt ratio. The 24.5% goodwill ratio is elevated — typical of a pharma that grows via tuck-in M&A — but creates impairment exposure if acquired franchises underdeliver against STELARA's patent cliff. The test over FY2025-27 is whether R&D (~19% of revenue) converts into Carvykti/Tremfya growth that offsets the STELARA decline, or whether management needs larger M&A to fill the gap.
Key Risks
STELARA generated $10B+ in FY2023 sales; biosimilar competition began entering in 2025. The 10-K states: 'loss of patent exclusivity for a product often is followed by a substantial reduction in sales as competitors gain regulatory approval for generic, biosimilar and other competing products.' STELARA is the single most important revenue event shaping FY2025-27 earnings.
Post-reorganization, J&J continues to manage talc-related claims through various legal vehicles. Accrued legal liabilities appear on the balance sheet and remain a tail risk, though materially reduced from peak exposure. The 10-K's legal proceedings disclosure remains extensive.
The 10-K documents ambitious pipeline assets — CARVYKTI (CAR-T multiple myeloma), TECVAYLI (bispecific antibody), expanded TREMFYA indications — but clinical trial and regulatory timelines create binary risk. Whether the pipeline fills the STELARA void by FY2027 determines the growth trajectory.
The 10-K warns: the FY2024 10-K cites regulatory action, production-quality deviations, safety issues, and labor-related events as potential manufacturing-disruption sources With 64 facilities and thousands of suppliers, correlated disruption risk (e.g., a raw material shortage affecting multiple products) exists.
Risk profile scores 64/100 (higher = safer). The STELARA patent cliff is the dominant near-term risk — the 10-K's own Risk Factors put this front and center. Per the FY2024 10-K Risk Factors, biosimilar competition in 2025 could materially affect FY2025-26 revenue, and J&J's pipeline response (CARVYKTI ramp, TREMFYA expansion) is the critical offset. The residual talc litigation exposure is smaller than peak but not extinguished. The 24.5% goodwill ratio adds impairment risk if the M&A-built portfolio underperforms. Talent-, manufacturing-, and regulatory-related risks are the steady-state headwinds the 10-K catalogs carefully.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.